目的 探讨复方苦参注射液联合替雷利珠单抗对非小细胞肺癌（NSCLC）化疗患者近期疗效、肝功能及免疫功能的影响。方法 选取中国人民解放军联勤保障部队第九二一医院收治的NSCLC化疗患者120例为观察对象，于2021年2月—2023年10月进行研究，按照治疗方案的不同分为对照组和试验组，各60例。两组患者均给予多西他赛联合顺铂化疗方案，对照组在此基础上给予替雷利珠单抗治疗，试验组在对照组基础上给予复方苦参注射液治疗，21 d为1个周期，共行6个周期治疗。比对两组近期疗效、肺功能指标、血清肿瘤标志物、免疫功能及不良反应发生情况。结果 试验组临床总有效率高于对照组［80.00%（48/60） vs 50.00%（30/60）］（P＜0.05）；治疗后试验组肺功能指标[用力肺活量（FVC）、气流量峰值（PEF）及1 s用力呼气容积（FEV1）]高于治疗前（P＜0.05）；治疗后试验组肿瘤标志物[糖类抗原125（CA125）、癌胚抗原（CEA）、鳞状细胞癌抗原（SCC）及细胞角蛋白19的可溶性片段（CYFRA21-1）]水平低于治疗前（P＜0.05）；治疗后试验组CD3⁺、CD4⁺、CD4⁺/CD8⁺水平呈现升高趋势，CD8⁺水平呈下降趋势，与对照组比较均具有显著差异（P＜0.05）；试验组骨髓抑制、呕吐及肝功能异常的发生率均低于对照组，但仅有肝功能异常情况比较无统计学意义（P＞0.05）。结论 对NSCLC化疗患者给予复方苦参注射液联合替雷利珠单抗治疗安全有效，改善肺功能指标，稳定血清肿瘤指标，提升免疫功能，且安全性高。

Objective To explore the effects of Compound Kushen Injection combined with tirelizumab on the short-term efficacy, liver function, and immune function of patients with non-small cell lung cancer (NSCLC) treated with chemotherapy. Methods A total of 120 patients with NSCLC treated with chemotherapy admitted to the 921st Hospital of PLA were selected as the observation objects, the study was conducted from February 2021 to October 2023. According to the different treatment schemes, they were divided into the control group and the experimental group, with 60 cases in each group. Both groups of patients were given a combination chemotherapy regimen of docetaxel and cisplatin. The control group was treated with tirelizumab on this basis, while the study group was treated with Compound Kushen Injection combined with tirelizumab on this basis, 21 d for one cycle, six cycles of treatment. The recent efficacy, lung function indicators, serum tumor markers, immune function, and incidence of adverse reactions were compared between two groups. Results The total clinical effective rate of the study group was higher than that of the control group [80.00% (48/60) vs 50.00% (30/60)] (P < 0.05). After treatment, the lung function indicators [forced vital capacity (FVC), peak expiratory flow (PEF), and forced expiratory volume in one second (FEV1)] in the study group were higher than those in the control group (P < 0.05); After treatment, the levels of tumor markers [carbohydrate antigen 125 (CA125), squamous cell carcinoma (SCC), Carcinoembryonic Antigen (CEA), and cytokeratin 19 fragment CYFRA21-1)] in the study group were lower than those in the control group (P < 0.05); After treatment, the CD3⁺, CD4⁺, CD4⁺/CD8⁺ data in the study group showed an increasing trend, while the CD8⁺ data showed a decreasing trend, with significant differences compared to the control group (P < 0.05); The incidence of bone marrow suppression, vomiting, and liver dysfunction in the study group was lower than that in the control group, but only the incidence of liver function abnormalities was not statistically significant (P < 0.05). Conclusion In patients with NSCLC treated with chemotherapy, the treatment of Compound Kushen Injection combined with tiralizumab is safe and effective, improved lung function indicators, stabilized serum tumor indicators, and enhanced immune function.

R979.1

长沙市科技计划项目（ kq1907150）